Please Wait.....
Report
Clinical Trials Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034
Market Report I 2025-02-27 I 183 Pages I Global Market Insights
The Global Clinical Trials Market was valued at USD 59 billion in 2024 and is projected to grow at a CAGR of 5.2% between 2025 and 2034. The rising demand for advanced treatment options, coupled with increasing investments in drug development, is driving market expansion. As chronic diseases such as cancer, diabetes, and cardiovascular conditions become more prevalent, pharmaceutical and biotechnology companies are ramping up their efforts to introduce innovative therapies. The surge in clinical research activity reflects a broader shift toward precision medicine and targeted treatments, further fueling growth in the clinical trials sector. Additionally, technological advancements such as artificial intelligence (AI), big data analytics, and decentralized trials are transforming clinical research, making trials more efficient and cost-effective. Regulatory support for fast-track drug approvals and increased collaboration between research institutions and healthcare providers are also contributing to market expansion. With an increasing focus on patient-centric approaches and adaptive trial designs, the clinical trials market is set to witness significant evolution in the coming years.
The clinical trials market is segmented by phase into Phase I, II, III, and IV. Among these, Phase III dominates the sector, accounting for USD 29.3 billion in 2024. These large-scale trials are critical for validating a drug's safety and efficacy before regulatory approval. Given their complexity and the need for diverse patient populations, Phase III studies are conducted across multiple locations to generate comprehensive clinical data. As companies push forward with novel drug formulations and biosimilars, the demand for extensive Phase III trials continues to rise, reinforcing this segment's leading position in the market.
Based on study design, clinical trials are categorized into interventional, observational, and expanded access studies. The interventional study segment led the market in 2024 and is anticipated to grow at a CAGR of 5% from 2025 to 2034. These studies play a pivotal role in determining the efficacy of new medical interventions by actively involving participants in controlled treatment protocols. By eliminating recall bias and offering a structured evaluation of treatment outcomes, interventional trials provide the highest level of clinical evidence. As a result, pharmaceutical companies and regulatory bodies increasingly rely on these studies to accelerate drug approvals and enhance treatment standards.
North America Clinical Trials Market held a 54.6% share in 2024, maintaining its dominance due to a high concentration of pharmaceutical and biotechnology companies. With the growing complexity of drug development, particularly in precision medicine and biologics, companies across the region are investing heavily in clinical trials to bring next-generation treatments to market. Strong regulatory frameworks, well-established research infrastructure, and increased funding for clinical studies further support North America's leadership in the sector. As demand for innovative therapies escalates, the region is poised for continued growth, reinforcing its pivotal role in global clinical research.
Report Content
Chapter 1 Methodology and Scope
1.1 Market scope and definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates and calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 360 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of chronic diseases across the globe
3.2.1.2 Growing demand for outsourcing clinical trials to CROs
3.2.1.3 Rise in government and non-government funding for clinical trials
3.2.1.4 Growing opportunities for conducting clinical trials in countries of Asia Pacific
3.2.2 Industry pitfalls and challenges
3.2.2.1 Lack of skilled workforce in clinical research
3.2.2.2 Infrastructural barriers in developing countries
3.2.2.3 Challenges faced in North America and Europe for conducting clinical trials
3.3 Growth potential analysis
3.4 Clinical trials volume analysis
3.4.1 Clinical trials volume analysis, by region, 2021 - 2024
3.4.2 Clinical trials volume analysis, by phase of development, 2021 - 2024
3.4.3 Clinical trials volume analysis, by indication, 2021 - 2024
3.5 Regulatory landscape
3.5.1 U.S.
3.5.2 Europe
3.5.3 Asia Pacific
3.5.3.1 Singapore
3.5.3.2 Malaysia
3.5.3.3 Indonesia
3.5.3.4 Thailand
3.5.3.5 South Korea
3.5.3.6 Philippines
3.6 Clinical trials - Asia Pacific advantage
3.7 Porters analysis
3.8 PESTEL analysis
Chapter 4 Competitive Landscape, 2024
4.1 Introduction
4.2 Company matrix analysis
4.3 Merger and acquisition landscape
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Phase, 2021 - 2034 ($ Mn)
5.1 Key trends
5.2 Phase I
5.3 Phase II
5.4 Phase III
5.5 Phase IV
Chapter 6 Market Estimates and Forecast, By Study Design, 2021 - 2034 ($ Mn)
6.1 Key trends
6.2 Interventional study
6.3 Observational study
6.4 Expanded access study
Chapter 7 Market Estimates and Forecast, By Service Type, 2021 - 2034 ($ Mn)
7.1 Key trends
7.2 Outsourcing service
7.3 In-house service
Chapter 8 Market Estimates and Forecast, By Therapeutic Area, 2021 - 2034 ($ Mn)
8.1 Key trends
8.2 Autoimmune disease
8.3 Oncology
8.4 Cardiology
8.5 Infectious disease
8.6 Dermatology
8.7 Ophthalmology
8.8 Neurology
8.9 Hematology
8.10 Other therapeutic areas
Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)
9.1 Key trends
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Poland
9.3.7 Netherlands
9.3.8 Switzerland
9.4 Asia Pacific
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.4.6 Singapore
9.4.7 Malaysia
9.4.8 Indonesia
9.4.9 Thailand
9.4.10 Philippines
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Argentina
9.6 Middle East and Africa
9.6.1 Saudi Arabia
9.6.2 South Africa
9.6.3 UAE
Chapter 10 Company Profiles
10.1 Charles River Laboratories
10.2 Clinipace
10.3 Eli Lilly and Company
10.4 ICON
10.5 IQVIA
10.6 Laboratory Corporation of America Holdings (Covance Inc)
10.7 Medpace
10.8 Merck & Co
10.9 Parexel International Corporation
10.10 Pfizer
10.11 SGS SA
10.12 Syneos Health
10.13 The Emmes Company
10.14 Thermo Fisher Scientific (PPD)
10.15 Veeda Clinical Research
10.16 Worldwide Clinical Trials
10.17 WuXi AppTech
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security